sorafenib has been researched along with Ventricular Dysfunction in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Biolato, M; Grieco, A; Lombardo, A | 1 |
| Kawabata, M; Kuroyanagi, J; Miyabe, M; Nishimura, Y; Shimada, Y; Tanaka, T; Umemoto, N; Zhang, B | 1 |
2 other study(ies) available for sorafenib and Ventricular Dysfunction
| Article | Year |
|---|---|
Ventricular thrombosis during sorafenib therapy for advanced hepatocellular carcinoma.
Topics: Aged; Anticoagulants; Antineoplastic Agents; Carcinoma, Hepatocellular; Enoxaparin; Heart Diseases; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Protein Kinase Inhibitors; Risk Factors; Sorafenib; Thrombosis; Treatment Outcome; Ultrasonography; Ventricular Dysfunction | 2013 |
Downregulation of stanniocalcin 1 is responsible for sorafenib-induced cardiotoxicity.
Topics: Adult; Animals; Antineoplastic Agents; Cardiotoxicity; Down-Regulation; Glycoproteins; Heart; Humans; Myocytes, Cardiac; Niacinamide; Phenylurea Compounds; Reactive Oxygen Species; Sorafenib; Ventricular Dysfunction; Zebrafish | 2015 |